{
    "startDate": "2021-01-01",
    "endDate": "2021-06-30",
    "year": "2021",
    "quarter": "Q2",
    "symbol": "CLBS",
    "data": {
        "bs": [
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 104679000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 104679000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 104679000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 84000
            },
            {
                "label": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2021 and December 31, 2020, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Other long-term liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 79000
            },
            {
                "label": "Total Caladrius Biosciences, Inc. stockholders' equity",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 104933000
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 12935000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1242000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 544893000
            },
            {
                "label": "Treasury stock, at cost; 11,080 shares at June 30, 2021 and December 31, 2020",
                "concept": "TreasuryStockValue",
                "unit": "usd",
                "value": 708000
            },
            {
                "label": "Commitments and Contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 108080000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecurities",
                "unit": "usd",
                "value": 93155000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecurities",
                "unit": "usd",
                "value": 93155000
            },
            {
                "label": "Liabilities and Equity, Total",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 108614000
            },
            {
                "label": "Total liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 3935000
            },
            {
                "label": "Noncontrolling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -254000
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 2614000
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 2614000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -17000
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 108614000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 1990000
            },
            {
                "label": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,528,538 and 19,389,413 shares at June 30, 2021 and December 31, 2020, respectively; and outstanding, 59,517,458 and 19,378,333 shares at June 30, 2021 and December 31, 2020, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 60000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 450000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -439295000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 3856000
            }
        ],
        "cf": [
            {
                "label": "Accounts payable, accrued liabilities and other liabilities",
                "concept": "clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
                "unit": "usd",
                "value": 176000
            },
            {
                "label": "Purchase of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 60000
            },
            {
                "label": "Share-based compensation",
                "concept": "IssuanceOfStockAndWarrantsForServicesOrClaims",
                "unit": "usd",
                "value": 867000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 1232000
            },
            {
                "label": "Net cash (used in) provided by operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -12602000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 33000
            },
            {
                "label": "Net proceeds from issuance of common stock",
                "concept": "ProceedsFromIssuanceOfCommonStock",
                "unit": "usd",
                "value": 85479000
            },
            {
                "label": "Proceeds from exercise of options",
                "concept": "ProceedsFromStockOptionsExercised",
                "unit": "usd",
                "value": 24000
            },
            {
                "label": "Net cash (used in) provided by investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -76294000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Tax withholding payments on net share settlement equity awards",
                "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
                "unit": "usd",
                "value": 184000
            },
            {
                "label": "Sale of marketable securities",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": 29558000
            },
            {
                "label": "Accretion on marketable securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -1133000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": -166000
            },
            {
                "label": "Net (decrease) increase in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": -3577000
            },
            {
                "label": "Purchase of marketable securities",
                "concept": "PaymentsToAcquireMarketableSecurities",
                "unit": "usd",
                "value": 105792000
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 85319000
            }
        ],
        "ic": [
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": -1508000
            },
            {
                "label": "Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)",
                "concept": "EarningsPerShareBasic",
                "unit": "usd/shares",
                "value": ""
            },
            {
                "label": "General and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 5828000
            },
            {
                "label": "Less - net income attributable to noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Other expense, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": -90000
            },
            {
                "label": "Total other (expense) income",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": -20000
            },
            {
                "label": "Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)",
                "concept": "EarningsPerShareDiluted",
                "unit": "usd/shares",
                "value": -0.27
            },
            {
                "label": "Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Operating loss",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -15233000
            },
            {
                "label": "Investment income, net",
                "concept": "InvestmentIncomeNet",
                "unit": "usd",
                "value": 70000
            },
            {
                "label": "Net loss before benefit from income taxes and noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -15253000
            },
            {
                "label": "Basic shares",
                "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
                "unit": "shares",
                "value": "N/A"
            },
            {
                "label": "Diluted shares",
                "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
                "unit": "shares",
                "value": 50862000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 9405000
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 15233000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Comprehensive income attributable to noncontrolling interests",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Comprehensive (loss) income",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -13749000
            },
            {
                "label": "Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -13749000
            },
            {
                "label": "Available for sale securities - net unrealized loss",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -4000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Net (loss) income",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -13745000
            },
            {
                "label": "Total other comprehensive loss",
                "concept": "OtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -4000
            }
        ]
    }
}